December 15th, 2015

Market Update (NASDAQ:BIIB): Biogen to Present at the Goldman Sachs Alzheimer’s Symposium

[Business Wire] – Biogen Inc. announced today that it will present at the Goldman Sachs Alzheimer’s Symposium. The webcast will be live on Monday, April 11, 2016 at 12:20p.m. ET. To access the live webcast, please visit Biogen’s Investors section at www.biogen.com/investors. Read more on this. Biogen Inc. (BIIB) , valued at $55.05B, started trading this morning at $255.05. A quick look at the market, the company’s stock traded between $251.45 and $256.71 with a trailing 52-week range being $242.07 to $437.00. BIIB shares are currently priced at 13.69x this year’s forecasted earnings, which makes them relatively expensive compared to the industry’s -5.78x earnings multiple for the same period. Consensus earnings for the current quarter by the 20 sell-side analysts covering the stock is an estimate of $4.45 per share, which would be $0.63 better than the year-ago quarter and a $0.12 sequential increase. Furthermore, our analysis shows the full-year EPS estimate to be $18.60, which would be a $1.59 better when compared to the last year’s annual results. The quarterly earnings estimate is predicated on a consensus revenue forecast of $2.75 Billion. If reported, that would be a 7.84% increase over the year-ago quarter. Recently, Citigroup Initiated BIIB at Buy (Feb 25, 2016). Previously, Credit Suisse Initiated BIIB at to Neutral. The average price target for BIIB shares by the analysts covering it is $350.28, which is 37.34% above where the stock opened. See more in (NASDAQ:BIIB) Similar Articles: Stock Update (NASDAQ:BIIB): Biogen to Present at the 34th Annual J.P. Morgan Healthcare Conference Company Update: Biogen Idec Inc (NASDAQ:BIIB) – Biogen Announces Departure of Tony Kingsley Company Update: Biogen Idec Inc (NASDAQ:BIIB) – Biogen Announces Webcast of Investor R&D Day
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.